Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294055 | 0.87 | MAOB (0.71) | EGFRERBB2KDM4EALDH1A1LMNA | |
| SCHEMBL6366056 | 0.84 | ACHE (0.56) | EGFRERBB2KDM4EALDH1A1LMNA | |
| SCHEMBL23052469 | 0.76 | KDM4E (0.77) | KDM4EALDH1A1LMNAACHEHTT | |
| SCHEMBL23052094 | 0.76 | KDM4E (0.77) | KDM4EALDH1A1LMNAACHEHTT | |
| SCHEMBL10362296 | 0.75 | EGFR (0.81) | EGFRERBB2KDM4EALDH1A1LMNA | |
| SCHEMBL20988910 | 0.74 | KDM4E (0.65) | EGFRERBB2KDM4EALDH1A1LMNA | |
| SCHEMBL17454724 | 0.74 | MAOB (0.82) | KDM4EALDH1A1LMNAMAOBMAOA | |
| SCHEMBL1896522 | 0.73 | CYP1A2 (0.68) | KDM4EALDH1A1LMNAHTTMAPT | |
| SCHEMBL9356499 | 0.73 | EGFR (0.86) | EGFRERBB2ACHEMAOBMAOA | |
| SCHEMBL11212856 | 0.73 | EGFR (0.75) | EGFRERBB2KDM4EALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | claimed |
| WO-2002089799-A2 | USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | claimed |
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6878729-B2 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | disclosed |
| WO-2002089799-A2 | USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, FLT4 | EGFR 801/4885ERBB2 1376/4885KDM4E 4362/4885 |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, TEK | EGFR 1020/4885ERBB2 1615/4885KDM4E 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.